Sign in
CompletedEarly phase 1

Methylphenidate and Response to Alcohol Cues Pilot Study

Key facts

Who runs it
University of Florida
Where
Gainesville, United StatesSee the site
Trial code
Status
Completed
Phase
Early phase 1
People taking part
31 people enrolled
Started
20 Mar 2024
Ended
1 Jul 2025
Type of study
Interventional, 2 groups
Treatments tested
  • Methylphenidate Pill
Record updated
10 February 2026

Who can take part

Age
18 years to 25 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Adults ages 18-25 years
  • Meets DSM-5 criteria for AUD
  • Meets DSM-5 criteria for ADHD
  • Fluent in English
  • Normal or corrected to normal vision

Who cannot take part

  • Participant routinely uses psychoactive drugs or medications except for non-dependent marijuana or nicotine use (due to common use of these substances in individuals with AUD)
  • Meets DSM-5 criteria for bipolar disorder, psychotic disorders, neurological disorders, or substance use disorders other than AUD
  • Self-reported history of high blood pressure over 140/90 or consistent readings of 140/90 or above upon arrival for a session
  • History of seizure disorder
  • Liver disease
  • Participant has contraindications for taking methylphenidate
  • Participant has contraindications for being in an MRI machine
  • Participant is currently pregnant or trying to become pregnant

Where in United States

  • University of FloridaGainesville, United States

About the trial

What the trial wants to find out

The purpose of this study is to determine whether changes in attention levels related to taking a single dose of a medication called methylphenidate, also known as Ritalin, affects responses to alcohol cues. The study will observe the effects of methylphenidate or a placebo on attentional bias and craving responses to alcohol cues through fMRI, EEG, and behavioral testing. Participants will be involved in one remote and two in-person sessions.

The 2 groups in the trial

  • crossover 1: methylphenidate, placeboOther group

    methylphenidate (single dose, oral, 20 mg, immediate release) followed by placebo (single dose, oral)

    Treatment: Methylphenidate Pill

  • crossover 2: placebo, methylphenidateOther group

    placebo (single dose, oral) followed by methylphenidate (single dose, oral, 20 mg, immediate release)

    Treatment: Methylphenidate Pill

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Methylphenidate and Response to Alcohol Cues (MARA) Pilot Study
Record updated
10 February 2026